Clinical efficacy of anti-amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results.

Alzheimers Dement (N Y) · 2025 · PMC11982174 · PMID 40225236

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

1 , 2 In prespecified secondary analyses, lecanemab showed a trend effect in favor of placebo and donanemab showed a trend effect in favor of treatment in the Apo Ε4 homozygote groups, with 95% confidence intervals (CIs) including the null value in both cohorts.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.